0 Items
Select Page

Human Metapneumovirus

Human Metapneumovirus (HMPV), along with Respiratory Syncytial Virus (RSV), is a common cause of lower respiratory tract infection in children worldwide. HMPV is an enveloped, negative single-stranded RNA virus belonging to the genus Metapneumovirus, of the family Pneumoviridae. The virus can affect the upper and lower respiratory tract of children and adults but can cause severe disease in children, the elderly and immunocompromised patients.

The Native Antigen Company offers highly specific HMPV monoclonal antibodies to support research and immunoassay development.

Human Metapneumovirus Background

Human Metapneumovirus (HMPV) is an enveloped, negative single-stranded RNA virus belonging to the genus Metapneumovirus, of the family Pneumoviridae. HPMV is closely related to Respiratory Syncytial virus (RSV), which belongs to the genus Orthopneumovirus within the same family (Alfonso, CL).

Human Metapneumovirus is globally widespread and is seasonal in temperate climates, being most active from winter to spring. Genomic analysis has shown that HMPV exists as two genotypes A and B, which are further divided into subgroups A1, A2 and B1, B2. Each of these subgroups has a distinct geographical distribution but may circulate separately or concurrently (Boivin, G).

Transmission of HMPV from person-to-person predominantly occurs through contact with airborne droplets from an infected individual, produced by coughing or sneezing. It can also be spread through contact with contaminated hands or surfaces.

Identified in 2001, HMPV, is one of the most common causes of paediatric lower respiratory tract infection. However, the virus can affect individuals of all ages infecting the upper or lower respiratory tract. The symptoms of HMPV infection include coughing, fever, wheezing and shortness of breath but in some cases bronchitis or pneumonia can develop. HMPV can cause severe life-threatening illness in paediatric, geriatric and immunocompromised patients (CDC).

Diagnosis of HMPV infection is commonly performed using molecular and serological techniques. Currently, there is no licensed vaccine available for the prevention of human Metapneumovirus infection and no antiviral treatment for the disease.

References

Afonso CL et al. 2016. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. Aug;161(8):2351-60

Boivin G et al. 2004. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis. Jun;10(6):1154-7

Centers for Disease Control and Prevention: The national respiratory virus and enteric virus surveillance system. Human metapneumovirus (HMPV) clinical features.

The Native Antigen company offers monoclonal antibodies specific to the Human Metapneumovirus (HMPV) and which are suitable for the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 14 =

Live Customer Feedback

Join our mailing list

* indicates required